Krista Kauppinen, Ph.D., J.D.
PRACTICE EXPERT, INTELLECTUAL PROPERTY and VICE PRESIDENT, LEGAL AFFAIRS
Intellectual property (IP) expert and registered patent attorney with over 10 years of combined experience in biologics and cell therapy patent prosecution and IP strategy at various stages of product development and commercialization.
Krista is an intellectual property (IP) expert with a focus and skillset for aligning her clients’ IP strategy with their business and corporate goals. She has over 10 years of combined experience in cell and gene-edited cell therapies, biologics patent prosecution and IP strategy.
Before joining Dark Horse Consulting Group in 2019, Krista was most recently Senior Director of Intellectual Property at Asterias Biotherapeutics. At Asterias, Krista was the sole person responsible for the company’s large, global patent portfolio, drafting new original applications and prosecuting to allowance and grant over 95 patent applications in the course of three years, including key US patents for the company’s clinical product candidates. She also oversaw the company’s licensing matters, including successfully negotiating a key license from a university for a second indication for the company’s AST-OPC1 product, and representing the company in various outbound licensing deals resulting in significant revenue in upfront and milestone license fees. She regularly advised the executive management of the company on IP matters and together with the process development team, devised a next-generation patent strategy for one of the company’s clinical product candidates.
Prior to Asterias, Krista worked as a patent agent at BioTime, where she also was the sole practitioner responsible for a large, global cell therapy patent portfolio. She began her career in intellectual property as an IP intern/patent practitioner (working part-time while in law school) at Affymetrix, Inc., and as a summer associate at the law firm Wilson Sonsini Goodrich & Rosati. She then worked several years as an independent IP consultant and patent agent for various Bay Area biotech clients on a diverse range of technologies including large molecule biologics, next-generation sequencing, and single nucleotide polymorphisms associated with human diseases and disorders.
Before going to law school and embarking on a career in intellectual property and patents, Krista earned a Ph.D. from Cornell University, where she conducted molecular biology research on the regulation and downstream signaling of a prototype member of an oncogene family. She also completed a postdoc at Cornell in a leading epigenetics laboratory, studying the epigenetic regulatory mechanisms of a cluster of imprinted genes and transcripts within the Rasgrf1 locus.
In addition to her IP consulting role, Krista also oversees all internal legal functions at Dark Horse Consulting Group as our Vice President, Legal Affairs.
- State Bar of California
- United States Patent and Trademark Office, Registered Patent Attorney
- Brideau CM#, Kauppinen KP#, Holmes R, Soloway PD. (2010) “A non-coding RNA within the Rasgrf1 locus in mouse is imprinted and regulated by its homologous chromosome in trans.” PLoS One 5(11): e13784. (#Authors contributed equally)
- Kamynina E#, Kauppinen K#, Duan F, Muakkassa N, Manor D. (2007) “Regulation of the proto-oncogenic Dbl by chaperone-controlled, ubiquitin-mediated degradation.” Mol Cell Biol 27(5):1809-22. (#Authors contributed equally)
- Morley S, Wagner J, Kauppinen K, Sherman M, Manor D. (2007) “Requirement for Akt-mediated survival in cell transformation by the Dbl oncogene.” Cell Signal 19(1):211-8.
- Kauppinen KP, Duan F, Wels JI, Manor D. (2005) “Regulation of the Dbl proto-oncogene by heat shock cognate protein 70 (Hsc70).”J Biol Chem 280(22):21638-44.
Asterias Biotherapeutics, Inc.
Senior Director, Intellectual Property
Director, Intellectual Property
BioTime, Inc. (Now Lineage Cell Therapeutics, Inc.)
Independent Patent Prosecution Consultant
Clients included public and privately held biotech companies developing large molecule biologics, next-generation sequencing technologies, and diagnostics panels using novel polymorphisms associated with human disease.
Wilson Sonsini Goodrich & Rosati, P.C.
Summer Associate, Patents and Innovation Strategies Group
IP Intern/Associate, Legal Department
University of California, Davis School of Law
J.D. (Coursework in patent and IP law)
Ph.D. in Biochemistry (Minors in Molecular Medicine and Cancer Cell Biology)
B.S. with Honors in Animal Science